Menu
← Oncology Approval Tracker
FDA DECISION ·
Penpulimab-kcqx
penpulimab-kcqx · Akeso Biopharma
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
As monotherapy for adults with metastatic non-keratinizing nasopharyngeal carcinoma after progression on or after platinum-based chemotherapy and at least one additional treatment line.
LAMPGEN ANALYSIS
Why it matters
The same-day monotherapy approval addresses a later, more heavily treated metastatic population.
What research teams should watch
Verify both prior platinum and an additional line, and recognize that the supporting single-agent study came from one country.
PRIMARY RECORDS